Hanneke M. J. Nijland

Exposure to Rifampicin Is Strongly Reduced in Patients with Tuberculosis and Type 2 Diabetes

Hanneke M. J. Nijland, Rovina Ruslami, Janneke E. Stalenhoef et al. · Clinical Infectious Diseases · 2006 · 241 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +8

Pharmacokinetics and Tolerability of a Higher Rifampin Dose versus the Standard Dose in Pulmonary Tuberculosis Patients

Rovina Ruslami, Hanneke M. J. Nijland, Bachti Alisjahbana et al. · Antimicrobial Agents and Chemotherapy · 2007 · 179 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +8

Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis

Hanneke M. J. Nijland, Rovina Ruslami, A. J. Suroto et al. · Clinical Infectious Diseases · 2007 · 170 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Pharmacokinetics of Antituberculosis Drugs in Pulmonary Tuberculosis Patients with Type 2 Diabetes

Rovina Ruslami, Hanneke M. J. Nijland, I. Gusti N. Adhiarta et al. · Antimicrobial Agents and Chemotherapy · 2009 · 122 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +7

High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets

Hanneke M. J. Nijland, Rafaëlla FA L'homme, Gerard A. Rongen et al. · AIDS · 2008 · 113 citations

Pharmacy, Pharmacokinetics, Pharmacology +13